NCT02586038View on ClinicalTrials.gov

STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

PHASE2CompletedINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2023

Study Completion Date

December 31, 2023

Conditions

Multiple Myeloma

Interventions

DRUG

MLN9708

DRUG

Dexamethasone

DRUG

Cyclophosphamide

DRUG

Thalidomide

Trial Locations (1)

15121

AO SS Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria

All Listed Sponsors

lead

Mario Boccadoro

OTHER

NCT02586038 - STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | Biotech Hunter | Biotech Hunter